Icosavax_Logo.jpg
Icosavax Announces $67.8 Million Registered Direct Offering of Common Stock
22 mai 2023 17h53 HE | Icosavax, Inc.
SEATTLE, May 22, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Icosavax_Logo.jpg
Icosavax Announces Positive Topline Interim Phase 1 Results for Bivalent VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults
22 mai 2023 17h37 HE | Icosavax, Inc.
–  IVX-A12 induced robust immune responses at Day 28 to both RSV and hMPV in older adults – –  IVX-A12 was generally well tolerated with no vaccine-related SAEs – –  First demonstration of hMPV...
Icosavax_Logo.jpg
Icosavax Granted FDA Fast Track Designation for IVX-A12
21 févr. 2023 08h00 HE | Icosavax, Inc.
SEATTLE, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Icosavax_Logo.jpg
Icosavax Provides Corporate Update and Anticipated Milestones for 2023
06 janv. 2023 08h00 HE | Icosavax, Inc.
- Recently reported positive six-month immunogenicity data for IVX-121 against RSV; first clinical evidence of potential differentiation on durability with company’s VLP platform - - Phase 1 study of...
Icosavax_Logo.jpg
Icosavax Reports Second Quarter 2022 Financial Results and Provides Corporate Update
15 août 2022 16h05 HE | Icosavax, Inc.
– Announced positive topline interim Phase 1/1b results for VLP vaccine candidate IVX-121 against respiratory syncytial virus (RSV) - – Icosavax plans to file an IND and initiate a Phase 1 trial...
Icosavax_Logo.jpg
Icosavax Announces Topline Interim Phase 1/2 Results for IVX-411 Against SARS-CoV-2
25 mars 2022 08h00 HE | Icosavax, Inc.
- Immunologic response observed in both SARS-CoV-2 naive and previously vaccinated subjects, but lower than expected and inconsistent with known data on company’s platform and VLP technology;...
Icosavax_Logo.jpg
Icosavax Provides Corporate Update and Anticipated Milestones for 2022
07 janv. 2022 08h00 HE | Icosavax, Inc.
SEATTLE, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Icosavax_Logo.jpg
Icosavax Appoints Dr. John Shiver to Board of Directors
05 janv. 2022 08h00 HE | Icosavax, Inc.
SEATTLE, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Icosavax_Logo.jpg
Icosavax to Participate in Upcoming Investor Conferences
11 nov. 2021 16h22 HE | Icosavax, Inc.
SEATTLE, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Icosavax_Logo.jpg
Icosavax Reports Second Quarter 2021 Financial Results and Provides Corporate Update
13 sept. 2021 16h05 HE | Icosavax, Inc.
- Initiated a Phase 1/2 clinical trial for IVX-411, a virus-like particle (VLP) displaying the SARS-CoV-2 receptor-binding domain - - Initiated a Phase 1/1b clinical trial for IVX-121, a VLP...